Compare VEON & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | DAWN |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 624.8M |
| IPO Year | 1996 | 2021 |
| Metric | VEON | DAWN |
|---|---|---|
| Price | $51.04 | $8.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $73.25 | $26.56 |
| AVG Volume (30 Days) | 100.2K | ★ 2.6M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 8.91 | N/A |
| Revenue | ★ $4,226,000,000.00 | $133,672,000.00 |
| Revenue This Year | $10.26 | $15.51 |
| Revenue Next Year | $7.61 | $49.99 |
| P/E Ratio | $5.74 | ★ N/A |
| Revenue Growth | 6.74 | ★ 31.11 |
| 52 Week Low | $34.55 | $5.64 |
| 52 Week High | $64.00 | $13.53 |
| Indicator | VEON | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 48.66 |
| Support Level | $49.82 | $7.90 |
| Resistance Level | $51.54 | $8.67 |
| Average True Range (ATR) | 1.54 | 0.52 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 34.84 | 26.54 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.